Table 1.
Summary of the characteristics of studies used for the simulation
| Study | Clinical situation | Treatment | Dosing regimen of rituximab | Number of assessable subjects | Availability of FCGR3A status | Reported PFS |
|---|---|---|---|---|---|---|
| Pivotal, 1998 (study A) [15, 17] | Relapsed/resistant FL (80%), CLL (18%), other (2%) | Rituximab | 4 × 375 mg m−2 week−1 | 151 | No | PFS of overall population and responders |
| Weng et al. 2004 (Study B) [22] | Relapsed/resistant FL | Rituximab | 4 × 375 mg m−2 week−1 | 87 | Yes | PFS of VV, VF, FF and F-carrier subgroups |
| van Oers et al. 2006 (Study C) [14] | Relapsed/resistant FL | CHOP or R-CHOP | 8 × 375 mg m−2 every 21 days with or without 375 mg m−2 maintenance at least every 3 months | 465 | No | PFS of CHOP and R-CHOP with or without rituximab maintenance |
| Cartron et al. 2002 (Study D) [20] | First-line FL | Rituximab | 4 × 375 mg m−2 week−1 | 49 | Yes | PFS of VV and F-carrier patients subgroups |
CHOP, cyclophosphamide, vincristine, adriamycin, prednisone; CLL, chronic lymphocytic leukaemia; F, 158-phenylalanine allele; FL, follicular non-Hodgkin's lymphoma; PFS, progression-free survival; V, 158-valine allele.